NANOG and glioblastoma: Previous studies also demonstrated that expression levels of OCT4, NANOG, and SOX2 were higher in poorly differentiated tumors than that of well-differentiated breast cancers, glioblastomas, and bladder carcinomas [37] as well as OSCC [17].